Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsReiterationPrice Target
Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.
Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.